Streetbeat News

Price Targets

PZZA

Loop Capital analyst Alton Stump reiterated a Buy rating on Papa John's International (NASDAQ:PZZA) and maintained a $114 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:15 pm

COHR

Northland Capital Markets analyst Tim Savageaux downgraded Coherent (NYSE:COHR) from Outperform to Market Perform and raised the price target from $38 to $45.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:10 pm

SPB

Wells Fargo analyst Chris Carey reiterates an Overweight rating on Spectrum Brands Holdings (NYSE:SPB) and raises the price target from $85 to $90.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 2:07 pm

TNXP

Zacks Small-Cap Research has set a $14 price valuation for Tonix Pharmaceuticals (TNXP), a significant increase from its current trading price.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 2:06 pm

KHC

Wells Fargo analyst Chris Carey has reiterated an Equal-Weight rating on Kraft Heinz (NASDAQ:KHC) and lowered the price target from $44 to $40.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 2:06 pm

CSGS

Northland Capital Markets analyst Nehal Chokshi initiates coverage on CSG Systems Intl (NASDAQ:CSGS) with an Outperform rating and a price target of $82.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:06 pm

XENE

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a $58 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:01 pm

PRTA

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Prothena Corp (NASDAQ:PRTA) and maintained a $129 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 2:00 pm

CMPS

Cantor Fitzgerald analyst Jonathan Fiore reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS) and maintained a $21 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 1:59 pm

CPRX

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 1:59 pm